文献速递妇科

真实世界登记与GOG/NRG肿瘤学随机III期临床试验中黑人与白人子宫内膜样子宫内膜癌患者的疾病进展、生存及分子差异

Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.
PubMed 文献 · Gynecol Oncol · 2024-04-08

比较黑人与白人子宫内膜样子宫内膜癌(EEC)患者在SEER、NCDB、GENIE及8项NCI随机III期试验中的结局与分子特征。黑人患者在真实世界登记中癌症相关死亡风险更高(SEER HR 2.04),NCDB匹配后HR 1.29;GENIE中黑人患者PI3K通路相关基因突变较少;试验中黑人患者死亡风险匹配后HR 1.32。

要点

  • SEER中黑人患者癌症相关死亡HR 2.04(95%CI 1.87-2.23),非癌死亡HR 1.22(1.09-1.36)。
  • NCDB匹配后黑人患者死亡HR 1.29(1.23-1.36),较匹配前1.52下降。
  • GENIE中黑人患者PTEN、PIK3R1、FBXW7、NF1、mTOR、CCND1及PI3K通路相关基因突变较少。

核心结论

  • 真实世界登记和随机试验中,黑人 vs 白人EEC患者在临床表现、结局和分子特征上存在差异。
  • 作者提出靶向药物开发、改变社会决定因素的策略及随机试验中多样化纳入是减少差异的途径。

研究设计与样本

  • 研究纳入SEER、NCDB、GENIE项目(v.13.0)及8项NCI资助的随机III期临床试验中接受子宫切除±辅助治疗的黑人与白人EEC患者。
  • SEER中黑人4397例 vs 白人47,959例;NCDB中黑人13,468例 vs 白人155,706例;GENIE中黑人109例 vs 白人1780例;随机试验中黑人187例 vs 白人2877例。
  • 估计癌症相关死亡、非癌死亡和全因死亡的风险比(HR)及95%置信区间(CI)。

主要发现

  • SEER中黑人 vs 白人癌症相关死亡HR 2.04(95%CI 1.87-2.23),非癌死亡HR 1.22(1.09-1.36)。
  • NCDB中黑人 vs 白人死亡HR 1.52(95%CI 1.46-1.58),倾向性评分匹配年龄、合并症、收入、保险、分级、分期、LVSI和治疗后降至1.29(1.23-1.36)。
  • GENIE中黑人 vs 白人患者PTEN、PIK3R1、FBXW7、NF1、mTOR、CCND1及PI3K通路相关基因突变较少;TP53和DNA修复相关基因突变频率及肿瘤突变负荷高状态在两组间相似。
  • 随机试验中黑人 vs 白人患者更可能有晚期或复发疾病、更高分级、更差体能状态和进展性疾病。
  • 随机试验中黑人 vs 白人死亡风险HR 2.19(95%CI 1.77-2.71),匹配分级、分期和治疗臂并平衡年龄和体能状态后为1.32(1.09-1.61)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Investigate racial disparities in outcomes and molecular features in Black and White patients with endometrioid endometrial carcinoma (EEC). METHODS: Black and White patients diagnosed with EEC who underwent hysterectomy ± adjuvant treatment in SEER, National Cancer Database (NCDB), the Genomics Evidence Neoplasia Information Exchange (GENIE) project (v.13.0), and eight NCI-sponsored randomized phase III clinical trials (RCTs) were studied. Hazard ratio (HR) and 95% confidence interval (CI) were estimated for cancer-related death (CRD), non-cancer death (NCD), and all-cause death. RESULTS: Black (n = 4397) vs. White (n = 47,959) patients in SEER had a HR (95% CI) of 2.04 (1.87-2.23) for CRD and 1.22 (1.09-1.36) for NCD. In NCDB, the HR (95% CI) for death in Black (n = 13,468) vs. White (n = 155,706) patients was 1.52 (1.46-1.58) dropping to 1.29 (1.23-1.36) after propensity-score matching for age, comorbidity, income, insurance, grade, stage, LVSI, and treatment. In GENIE, Black (n = 109) vs. White (n = 1780) patients had fewer PTEN, PIK3R1, FBXW7, NF1, mTOR, CCND1, and PI3K-pathway-related gene mutations. In contrast, TP53 and DNA-repair-related gene mutation frequency as well as tumor mutational burden-high status were similar in Black and White patients. In RCTs, Black (n = 187) vs. White (n = 2877) patients were more likely to have advanced or recurrent disease, higher grade, worse performance status and progressive disease. Risk of death in Black vs. White patients in RCTs was 2.19 (1.77-2.71) persisting to 1.32 (1.09-1.61) after matching for grade, stage, and treatment arm while balancing age and performance status. CONCLUSIONS: Differences exist in clinical presentation, outcomes, and molecular features in Black vs. White patients with EEC in real-world registries and RCTs. Targeted-drug development, strategies to modify social determinants, and diverse inclusion in RCTs are approaches to reduce disparities.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kopelman ZA, Tian C, Tumas J, et al. Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials. Gynecol Oncol. 2024. PMID: 38593674. doi:10.1016/j.ygyno.2024.03.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。